Ind-Swift Limited (INDSWFTLTD) - Cash Flow Conversion Efficiency

Latest as of March 2025: -0.039x

Based on the latest financial reports, Ind-Swift Limited (INDSWFTLTD) has a cash flow conversion efficiency ratio of -0.039x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs158.56 Million ≈ $1.71 Million USD) by net assets (Rs-4.02 Billion ≈ $-43.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Ind-Swift Limited to measure how much of total assets are equity-financed.

Ind-Swift Limited - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Ind-Swift Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INDSWFTLTD cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Ind-Swift Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ind-Swift Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Moksh Ornaments Limited
NSE:MOKSH
-0.121x
Magmatic Resources Ltd
AU:MAG
-0.148x
PT Dafam Property Indonesia Tbk
JK:DFAM
1.537x
Pioneer Lithium Ltd
AU:PLN
N/A
Citatah Tbk
JK:CTTH
-0.063x
EBANG INTL HLDGS (NEW) A
F:7EBA
N/A
Standard Uranium Ltd.
V:STND
-0.056x
Venzee Technologies Inc
V:VENZ
-0.012x

Annual Cash Flow Conversion Efficiency for Ind-Swift Limited (2006–2025)

The table below shows the annual cash flow conversion efficiency of Ind-Swift Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Ind-Swift Limited worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs-4.02 Billion
≈ $-43.51 Million
Rs158.56 Million
≈ $1.71 Million
-0.039x -78.15%
2024-03-31 Rs-6.91 Billion
≈ $-74.71 Million
Rs152.83 Million
≈ $1.65 Million
-0.022x +78.66%
2023-03-31 Rs-7.05 Billion
≈ $-76.21 Million
Rs730.46 Million
≈ $7.90 Million
-0.104x -48.73%
2022-03-31 Rs-7.20 Billion
≈ $-77.90 Million
Rs502.02 Million
≈ $5.43 Million
-0.070x +41.76%
2021-03-31 Rs-6.95 Billion
≈ $-75.18 Million
Rs831.93 Million
≈ $9.00 Million
-0.120x -146.68%
2020-03-31 Rs-7.13 Billion
≈ $-77.12 Million
Rs345.96 Million
≈ $3.74 Million
-0.049x +23.32%
2019-03-31 Rs-6.76 Billion
≈ $-73.14 Million
Rs427.86 Million
≈ $4.63 Million
-0.063x -485.49%
2018-03-31 Rs-6.63 Billion
≈ $-71.72 Million
Rs71.66 Million
≈ $774.98K
-0.011x -486.50%
2017-03-31 Rs-6.16 Billion
≈ $-66.56 Million
Rs-17.21 Million
≈ $-186.10K
0.003x -99.43%
2016-03-31 Rs-2.45 Billion
≈ $-26.54 Million
Rs-1.19 Billion
≈ $-12.92 Million
0.487x +122.46%
2015-03-31 Rs-395.00 Million
≈ $-4.27 Million
Rs855.75 Million
≈ $9.25 Million
-2.166x -328.56%
2014-03-31 Rs1.08 Billion
≈ $11.72 Million
Rs1.03 Billion
≈ $11.11 Million
0.948x +240.79%
2013-03-31 Rs2.17 Billion
≈ $23.50 Million
Rs-1.46 Billion
≈ $-15.82 Million
-0.673x -470.93%
2011-03-31 Rs3.30 Billion
≈ $35.67 Million
Rs598.64 Million
≈ $6.47 Million
0.182x +9122.60%
2010-03-31 Rs2.80 Billion
≈ $30.26 Million
Rs-5.63 Million
≈ $-60.88K
-0.002x -100.95%
2009-03-31 Rs2.42 Billion
≈ $26.12 Million
Rs509.22 Million
≈ $5.51 Million
0.211x +76.03%
2008-03-31 Rs1.78 Billion
≈ $19.27 Million
Rs213.43 Million
≈ $2.31 Million
0.120x +316.53%
2007-03-31 Rs1.49 Billion
≈ $16.09 Million
Rs-82.28 Million
≈ $-889.78K
-0.055x -206.94%
2006-03-31 Rs1.30 Billion
≈ $14.03 Million
Rs67.09 Million
≈ $725.56K
0.052x --

About Ind-Swift Limited

NSE:INDSWFTLTD India
Market Cap
$9.23 Million
Rs853.64 Million INR
Market Cap Rank
#27226 Global
#1521 in India
Share Price
Rs15.76
Change (1 day)
+6.13%
52-Week Range
Rs14.85 - Rs16.36
All Time High
Rs33.25
About

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin… Read more